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Abstract
Summary Postmenopausal osteoporosis is the most common
metabolic bone disease with important genetic factors. We
evaluated the frequency of polymorphism 283G/A of the
vitamin D3 VDR gene receptor. The study included 800 wom-
en at the postmenopausal (505) and reproductive (295) age.
Statistically significant changes, depending on the genotype,
were shown.
Introduction Postmenopausal osteoporosis is the most com-
mon metabolic bone disease of strong genetic origin with
population variability determined by the interaction of genetic
and environmental factors. Recognition of different genetic
variants underlying development of osteoporosis would make
it possible to administer individual symptomatic treatment as
well as early prophylactics of osteoporosis.
Methods The aim of the study was to evaluate the frequency
of polymorphism 283G/A of the vitamin D3 VDR gene recep-
tor and assessment of its relations with the clinical parameters
of osseous turnover and degree of postmenopausal
osteoporosis.
The study included 800 women at the postmenopausal
(505) and reproductive (295) age throughout the
Wielkopolska region in Poland. The postmenopausal group
included women with osteoporosis and osteopenia and the
healthy ones. Women at the reproductive age were healthy.
Frequency of the tested gene polymorphism was evaluated in
the group where bone mineral density (BMD) was marked
and in the control group.
Results The obtained test results pointed to correlation of
polymorphism VDR 283G/A with the BMD scores for the
lumbar vertebrae in women with osteopenia and osteoporosis,
therefore the ones at risk of fractures. Vitamin D receptor
(VDR) polymorphism correlated with reduced BMD values.
Conclusions Polymorphism 283G/A of the vitamin D3 recep-
tor gene has been proved to be the genetic factor of postmen-
opausal osteoporosis. The polymorphism mentioned above
has been proved to be a factor of mineral bone density changes
of women.
Keywords Age . Females . Osteoporosis . Polymorphism .
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Introduction
Vitamin D is a fat soluble steroid compound performing a
variety of functions in the human body. The active form of
vitamin D, produced in the kidneys, has a systemic effect. The
vitamin produced by other cells performs within the cells or
locally. Such effects are the so-called nonclassic functions of
vitamin D, such as effect upon proliferation, differentiation, or
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apoptosis [1, 2]. Both, the classical functions, i.e., effect upon
calcium-phosphate management and the nonclassical ones are
imposed by the nuclear receptor (VDR), regulating directly
the gene expression [3].
Vitamin D receptor (VDR) belongs to the nuclear recep-
tors, activated by a ligand and performing as transcription
factors [4, 5].
Reports of the recent years pointed to the occurrence of
vitamin D receptor polymorphism [6]. Initially, VDR poly-
morphism was analysed in disease associated with bone me-
tabolism, yet the studies were gradually extended to comprise
the role of vitamin D3 receptor in the pathogenesis of other
disorders, including the neoplastic diseases [6, 7].
The VDR gene is localized in chromosome 12q12-14. It
contains polymorphisms with a functional role. Mutations of
the VDR gene may be important for the effect of vitamin D
upon the cells. The available literature on the effect of con-
centration and taking vitamin D upon activity, progression,
and prognosis in some diseases is scarce, comprises few
variables, and often brings contradictory data. The existence
of several polymorphisms in the VDR gene has been de-
scribed using different restriction enzymes. Examples of these
include the Tru9I, TaqI, BsmI, EcoRV, and ApaI. All these
polymorphisms are located between the exons 8 and 9. A
different case of RFLP is the so-called FokI. This polymor-
phism was described in the exon 2.
Polymorphisms of four loci within the VDR gene are asso-
ciated with biological changes in bone mass and density.
Those are polymorphisms BsmI, TaqI, ApaI, and FokI.
A dependency was proved to exist between the mineral
density of bones and the variants of the VDR gene, coding the
receptor protein for vitamin D. The physiological mechanism
of the effect of vitamin D receptor genotype polymorphism
upon the mineral density of bones has not been fully recog-
nized yet.
Very early effect of vitamin D upon osteogenesis was
proved upon discovery of a receptor of this vitamin on the
mesenchymal cell. They had been revealed before differ-
entiation to the osseous tissue was started. 1,25-
dihydroxycholecalciferol stimulates differentiation of os-
teoblasts, enhances expression of VDR receptors on a
growing bone, and stimulates synthesis of type I collagen.
It has also been proved that renal metabolite has an
intermediate role in stimulation of osteolysis through pro-
cesses associated with the RANKL pathway and their
effect upon both osteoclastogenesis and bone resorption
[8, 9]. It is known that the effect of polymorphism on
bone mineral density is not explicit and may interfere with
other factors of both genetic and environmental nature.
This turned the scientists’ efforts towards effects brought
by polymorphisms within the VDR gene, commencing a
new era in studies aimed at identification of genes in-
volved in pathogenesis of osteoporosis.
Therefore, the objective of this study was to define the role
of relations of the evaluated gene with the process of post-
menopausal osteoporosis, bone density as well as other indi-
vidual and clinical parameters. The aim was to evaluate fre-
quency of gene VDR polymorphism, coding vitamin D3 re-
ceptor in the female postmenopausal group. The analysis
comprised relation of the evaluated genetic variant to the
degree of the osseous changes and the osseous turnover, as
well as assessment of the role of the evaluated genetic poly-
morphisms in the etiopathogenesis of osteoporosis. We hy-
pothesized that the polymorphism 283G/A of the gene recep-
tor of vitamin D3 is closely related to changes in bone density.
Materials and methods
Test group
The study comprised a group of unrelated Caucasian women
inhabiting the region of Wielkopolska. Investigations includ-
ed 800 women at the postmenopausal age (505) and the
reproductive one (295). The postmenopausal group included
314 women with osteoporosis, 110 with osteopenia, and 81
healthy individuals. Densometric measurements were per-
formed to define the bone mineral density (BMD) as well as
T-score, Z-score, mean bone mineral density index as com-
pared to the mean value for young adult women (YA-young
adults) and mean bone mineral density as compared to the
mean value for a given age (AM-age matched). Additionally,
body weight and height were measured to calculate the body
mass index.
Detailed history of each patient was taken to gain informa-
tion on the diseases developed, medication prescribed, age of
first and last menstruation, number of deliveries, birth weight
as well as smoking habits.
Qualified for genetic tests were those women in
whom menopause occurred at least a year ago, who
did not receive therapies possibly influencing the bone
mass, including selective estrogen receptor modulators—
SERM, calcitonin, biposphonates, heparin, steroids, thy-
roid hormones, antiepileptic drugs, GnRH analogs,
tibolon, and underwent no hormonal replacement thera-
py (HRT). Excluded from the study were patients fol-
lowing bilateral ovariectomy as well as those suffering
from endocrine and metabolic disorders, hematological
disease, neoplastic conditions, renal disorders,
autoimmunologic diseases, or connective tissue diseases,
as the above could possibly influence the bony mass.
Additionally, a group of Caucasian women at the repro-
ductive age was examined (mean age 27.5±4.7). Con-
sent to perform the study was obtained from the Bio-
ethical Committee.
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Bone mineral density (BMD) was measured at the lumbar
vertebrae, from vertebra L2 through L4, employing dual en-
ergy X-ray absorptiometry (DXA). Densometric tests were
performed with the use of LUNAR DPX 100 unit (by Lunar
Corporation, Madison, USA). BMD scores were expressed as
grams per square centimeter and presented as T-score and Z-
score indices, referring to mean BMD values for a given age
group. BMD scoring between one standard deviation from the
mean age referring to the peak bone mass, measured by the
DEXA method, was considered normal (T-score from +1 to
−1).
Tests comprised the influence of the evaluated polymor-
phism upon T-score, Z-score, L2–L4 AM, L2–L4 YA, L2–L4
BMD, BMI as well as other clinical parameters. Results were
presented as arithmetic mean with standard deviation. For this
purpose, ANOVA analysis of variance was employed. Values
adopted as statistically significant were those higher than
p<0.05.
Analysis of gene VDR polymorphism by real-time PCR
Analysis of polymorphism of 283G/A of gene VDR was
performed by real-time PCR with the use of LightCycler®
480 designed to ensure quick and accurate polymerase
chain reaction. For such procedures, HybProbe hybridiza-
tion probes were used along with LightCycler® 480 Basic
to evaluate the results. Genotyping, i.e., detection of sin-
gle nucleotide polymorphism of the evaluated genes
employed fluorescence measurements taken upon analysis
of the melting curve following PCR. LightSNiP set with
phials containing proper concentration of starters and
probes specific for the amplified fragment was used to
test polymorphism of gene VDR . Preparation of
LightSNiP used for real-time PCR followed the manufac-
turers’ instructions.
The reactions were performed, respectively, through-
out 45 cycles for the gene evaluated, covering particular
stages of amplification, which was followed by melting
of the reaction’s products once the temperature reached
95 °C. The genotype was analysed on the basis of the
melting curve. The genotype frequency observed upon
the recent study was compared to the values expected for
genotype distribution at Hardy-Weinberg’s equilibrium,
using chi-square—χ2 test. The formula applied was
p2+2pq+q2=1. Results were presented with 95 % confi-
dence interval (95 % CI).
Statistical analysis of the results employed the software
SPSS 17.0 PL for Windows. The database was supplied
with clinical parameters of the patients, the genotype
frequency, and the evaluated polymorphism allele. The
study was planned according to statement of Human and
Animal Rights. It has been approved by the local Bioeth-
ical Committee in Poznan (no. 1415/03 (158/06)).
Results
Polymorphism VDR 283G/A
Analysis of frequency of homozygous AA and GG genotypes
and the heterozygous AG in polymorphism of 283G/A
(G283A) of gene VDR showed comparable results in the
group with osteoporosis and in healthy postmenopausal fe-
males. No statistically significant differences were noted be-
tween the groups. More frequent in women with osteoporosis
was the heterozygous AG genotype while in healthy women
dominating was genotype AA (Tables 1 and 2).
Frequency of AA and GG genotypes and the heterozygous
AG genotype in polymorphism 283G/A (G283A) of gene
VDRwas comparable in the reproductive age group of women
with osteoporosis and in the healthy group. No statistically
significant differences were noted between the groups. More
frequent in women with osteoporosis was the heterozygous
AG genotype, while in young, healthy women higher frequen-
cy was shown for the AA genotype (Tables 1 and 3).
Frequency of the homozygous GG genotype in polymor-
phism 283G/A (G283A) of gene VDR differed significantly in
women with osteopenia and in the healthy female in postmen-
opausal age. Higher values were observed in the healthy,
postmenopausal group (Table 2). Frequency of AG genotype
was slightly higher in osteopenic women. Frequency of AA
genotype was comparable in both evaluated groups.
Analysis of frequency of homozygous AA and GG geno-
types and the heterozygous AG in polymorphism of 283G/A
(G283A) of gene VDR showed the results for genotype AA
and AG comparable in women with osteoporosis and in the
osteopenic group (Tables 1 and 2). Genotype GG was more
frequent in women with osteoporosis. Most frequent in both
female groups was genotype AG.
Analysis of frequency of homozygous AA and GG geno-
types and the heterozygous AG in polymorphism of 283G/A
(G283A) of gene VDR showed the frequency of GG genotype
comparable in women with osteopenia and osteoporosis and
in the healthy, postmenopausal group (Tables 2 and 3). The
homozygous AA genotype was more frequent in healthy
women while AG genotype prevailed in ill females. Most
frequent in both female groups was the heterozygous AG
genotype in ill females and AA in healthy women.
Analysis of frequency of homozygous AA and GG geno-
types and the heterozygous AG in polymorphism of 283G/A
(G283A) of gene VDR showed comparable results in women
with osteopenia and concurrent osteoporosis and in the
healthy females at reproductive age (Table 3). No statistically
significant differences were noted.
Frequency of homozygous AA and GG genotypes and
the heterozygous AG in polymorphism of 283G/A
(G283A) of gene VDR was comparable in healthy, post-
menopausal women, and in the reproductive age group
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(Tables 2 and 3). In both female groups, genotype AAwas
more frequent.
Influence of VDR 283G/A polymorphism on parameters
of the evaluated women
Results presented in Tables 4 and 5 show the value of BMD
L2–L4 YA (%) in the evaluated female osteopenic group was
significantly higher in women with genotype AA of polymor-
phism G283A of gene VDR, as compared to the same param-
eter in females with genotype AG and GG. The same table
shows that the value of BMD L2–L4 AM (%) in patients with
genotype AA of the evaluated gene is lower than with geno-
type GG, i.e., reversely to BMD L2–L4 YA (%).
Results presented in Table 6 point to the values of BMD
L2–L4 AM (%) in the evaluated female population with
osteoporosis, significantly lower in women with genotype
AA of polymorphism G283A of gene VDR, as compared to
the same parameter in women with genotype GG.
Discussion
It is estimated that one billion people worldwide, in particular
the elderly inhabitants of US and European cities, shows
vitamin D deficiency [10–12]. The level of calcidiol is too
low even in 30–50 % of inhabitants of such highly sun-
exposed regions like the United Arab Emirates, Turkey, or
India [13]. People of those regions are used to covering their
bodies, restricting therefore synthesis of vitamin D. Biologi-
cally active, double hydroxylated form of vitamin D—
calcitriol—as well as its analogs effect the target cells through
VDR.
Lack of direct association between low serum concentra-
tion of vitamin D and aggravation of osteopenia and osteopo-
rosis led to the research into other factors which could account
for the mechanism of development of hepatic osteodystrophy.
Recently, attention has been paid to polymorphism of the
receptor gene of vitamin D as a dependency has been shown
between bone mineral density and the VDR gene variant
coding the receptor protein for vitamin D. So far, the physio-
logical mechanism of the effect of polymorphism of receptor
genotype for vitamin D upon bone mineral density has not
been recognized. It is likely to be associated with disorders of
intestinal calcium absorption [14]. It is claimed that in some
diseases, a large group of patients shows excessive or lower
presence of particular variants of the VDR gene. This was
proved by Springer et al. [15], who observed relations be-
tween vitamin D receptor genotype and development of he-
patic dystrophy. In patients with allele T of the VDR gene, 2–
3-fold higher risk of spinal fracture was noted.
Recently, some more reports have confirmed the genetic
background of bone mineral density. Even if information on
the effect of a given gene or genes are contradictory [16], the
scientists do agree that bone mineral density depends in 75–
80% on the genetic factors [16, 17]. So far, no single genewas
found to prevail over others in the determination of bone
mineral density. It is most probably a multi-gene relation
[16–18]. Among the number of genes, tested most frequently
Table 1 The frequency of occur-
rence of polymorphism of the
VDR 283G/A genotypes in wom-
en with osteoporosis and without


















GG 56 (20.1) 12.2 15.5–23.4 23 (14.2) 12.7 11.0–16.5
AG 121 (43.5) 45.4 37.2–52.0 70 (42.9) 45.8 32.9–45.3
AA 101 (36.3) 42.4 29.3–44.7 70 (42.9) 41.5 36.6–48.7
Total 278 (100) 100 163 (100) 100
Table 2 The frequency of occur-
rence of polymorphism of the
VDR 283G/A genotypes in wom-


















GG 12 (11.4) 11.8 8.8–16.2 11 (19.0) 12.7 15.2–24.9
AG 48 (45.7) 45.0 35.6–55.8 22 (37.9) 45.8 31.3–41.6
AA 45 (42.9) 43.2 34.8–51.3 25 (43.1) 41.5 33.3–50.2
Total 105 (100) 100 58 (100) 100
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was the vitamin D receptor gene [19, 20] or genes coding
collagen [21]. For such reasons, this study chose the gene
coding the receptor for active vitamin D metabolites recog-
nized as one with polymorphism likely to affect the osseous
tissue density in the patients.
Our studies have shown that females with osteoporosis and
osteopenia, with genotype AA, manifest lower values of
BMD L2–L4AM, as compared to other genotypes. This
proves the relation of vitamin D receptor polymorphism to
lower bone density.
Results of the recent study are comparable to those de-
scribed in literature. Most of the contributions showed no
influence of the VDR genotype upon the mineral density of
the lumbar vertebrae [22, 23]. Only Sainz et al. [24], who
studied premature Mexican girls, pointed to the effect of the
VDR gene on BMD throughout the L2–L4 section.
Frequency of BsmI polymorphism of the VDR gene in
groups evaluated during this study was consistent with
Hardy-Weinberg equilibrium. It was observed that distribution
of frequency of particular BsmI polymorphism genotype was
the same as one observed many years ago by Hustmyer et al.
[25] who evaluated the Caucasian population. Frequency of
heterozygotes observed in the recent study was also close to
values obtained in the quoted research. The same team ob-
served that the black and yellow race populations showed
significant differences in frequency of both alleles (21 and
6 %, respectively for allele B).
In the present study, the presence of GG genotype of the
VDR gene was statistically lower as compared to other geno-
types. It is possible that the result is due to elevated supply of
vitamin D3, as suggested by Japanese scientists, who noted
some relation between vitamin and calcium consumption and
the phenotype [26].
Similar results were obtained following evaluation of the
female population in the USA, which showed relations be-
tween the VDR genotype and the risk of osteoporous bone
fractures [27–29]. On the other hand, no relation between
bone fractures and the VDR gene polymorphism was found
in European populations [30]. Evaluation of Dutch population
showed that allele B of BsmI polymorphism of the VDR gene
is associated with predispositions to bone fractures [29]. Re-
sults confirming correlation of the evaluated alleles with BMD
and higher risk of bone fractures were delivered by another
Dutch research center [27].
Table 3 The frequency of occur-
rence of polymorphism of the
VDR 283G/A genotypes in wom-
en with osteoporosis and


















GG 68 (17.8) 15.9 16.0–21.9 51 (17.4) 13.6 13.2–22.2
AG 169 (44.1) 47.9 37.3–55.3 113 (38.9) 46.5 32.7–41.6
AA 146 (38.1) 36.2 31.4–47.8 128 (43.7) 39.9 35.9–50.2
Total 383 (100) 100 292 (100) 100
Table 4 Characteristic of the
population of healthy women in
postmenopausal age taking part in
the study of the VDR 283G/A
polymorphism
Genotype GG AG AA
T-score −0.09±0.60 0.06±0.68 0.18±0.59
Z-score 0.65±0.90 0.70±0.53 0.60±0.77
Body mass (kg) 66.93±8.54 70.28±8.37 68.08±10.33
Height (cm) 163.73±4.58 164.04±5.02 162.42±4.16
BMI (kg/m2) 25.01±4.50 25.70±3.98 25.06±4.13
Age 55.70±9.02 55.60±8.87 52.17±8.00
Birth weight 3508.71±492.32 3408.66±500.32 3819.79±473.15
Reproductive years 37.01±5.01 37.56±4.65 39.06±5.06
Age of menarche 13.13±1.55 13.02±1.72 14.08±1.37
Last menstrual period age 50.18±4.73 50.07±5.06 51.37±4.40
Number of pregnancies 1.91±1.29 1.97±1.07 1.99±1.33
Years after menopause 7.01±4.82 7.03±5.20 8.03±4.92
BMD L2–L4 (g/cm2) 1.19±0.07 1.29±0.08 1.10±0.19
BMD L2–L4 YA (%) 101.02±7.71 96.02±6.84 106.51±7.34
BMD L2–L4 AM (%) 100.96±8.73 104.63±10.71 113.54±9.57
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For a long time now, the VDR gene has been accepted
as one of the major ‘candidate genes’ involved in devel-
opment of osteoporosis. Evidence of genetic susceptibility
to osteoporosis could appear as one of the methods used
to identify individual predispositions to this disease and as
an early prophylactic measure. It should be remembered,
however, that in many cases it is the environmental factor
that determines development of such disorders. Environ-
mental factors may affect the osseous mass in a variety of
ways. Therefore, the evaluated populations should be
tested to find any links between the genotype and the
phenotype. Some contributions discussing such correla-
tions have already been published [31, 32].
Evaluation of Polish population showed prevailing al-
lele T of TaqI polymorphism of the VDR gene in patients
with osteoporosis [33]. As claimed by the authors, this
suggests relation between VDR polymorphism and the
risk of osteoporosis. Data regarding the European and
Mexican population bring similar results to confirm such
relation [34]. Some reports point, however, to the lack of
relation between the VDR gene polymorphism and bone
density [35]. Also, evaluation of Chinese population has
not proved significant dependencies between the VDR
gene and BMD index. Such diversity of results needs to
be clarified, including differences between populations or
the environmental factors which could alter genetic
Table 5 Characteristic of the
women population with
osteopenia taking part in the study
of the VDR 283G/A
polymorphism
Significance of bold entries was
observed by post hoc analysis
*p<0.05
Genotype GG AG AA
T-score −1.78±0.53 −1.94±0.32 −1.60±0.47
Z-score −0.90±0.52 −0.80±0.39 −0.75±0.46
Body mass (kg) 64.39±9.51 67.01±8.52 65.58±9.84
Height (cm) 161.02±4.76 164.13±4.72 163.38±4.87
BMI (kg/m2) 23.02±3.73 25.62±4.03 24.82±3.92
Age 53.01±8.15 56.13±4.78 54.82±3.92
Birth weight 3298.12±523.48 3225.81±491.73 3280.15±527.75
Reproductive years 39.26±4.82 37.82±5.12 37.11±4.72
Age of menarche 13.86±1.02 12.47±1.78 13.01±1.60
Last menstrual period age 47.77±4.78 50.36±5.01 52.82±4.49
Number of pregnancies 1.90±1.41 1.95±1.15 1.91±1.38
Years after menopause 7.71±4.92 7.20±5.19 7.03±4.77
BMD L2–L4 (g/cm2) 0.99±0.05 0.97±0.06 0.92±0.04
BMD L2–L4 YA (%)* 76.01±4.05 77.28±4.80 90.21±4.35
BMD L2–L4 AM (%)* 95.62±8.67 88.35±8.44 82.66±7.45
Table 6 Characteristic of the
women population with osteopo-
rosis taking part in the study of the
VDR 283G/A polymorphism
Significance of bold entries was
observed by post hoc analysis
*p<0.05
Genotype GG AG AA
T-score −3.02±0.44 −3.32±0.92 −3.10±0.26
Z-score −1.60±0.60 −1.65±0.52 −1.58±0.40
Body mass (kg) 60.01±5.47 62.02±7.58 64.14±6.82
Height (cm) 160.96±4.73 162.29±4.19 160.30±5.00
BMI (kg/m2) 24.04±4.15 24.47±3.70 23.80±4.01
Age 56.11±7.52 56.03±8.38 58.23±7.23
Birth weight 2930.01±528.73 3072.82±466.02 3306.28±506.28
Reproductive years 36.03±4.62 36.92±5.13 36.00±4.15
Age of menarche 13.59±1.87 13.06±1.29 12.52±1.06
Last menstrual period age 48.98±4.65 48.62±4.73 51.06±5.03
Number of pregnancies 2.62±1.29 1.89±1.00 1.96±1.14
Years after menopause 10.02±5.14 11.36±6.03 13.27±5.87
BMD L2–L4 (g/cm2) 0.83±0.06 0.83±0.04 0.80±0.02
BMD L2–L4 YA (%) 68.23±5.01 72.53±5.31 70.81±4.88
BMD L2–L4 AM (%)* 81.15±8.33 76.28±7.63 66.61±6.73
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predispositions, eventually manifested in different pheno-
types [36, 37].
Remarkable discrepancies have been noted upon compar-
ison of results gained by various teams, investigating this
polymorphism of vitamin D receptor, with regard to bone
conditions. The major reason, however, is the number of
patients comprising the studies. Let us emphasize that our
tests have included 800 patients, which places the study
among a few projects covering such a large population. It
should also be pointed that the population evaluated was
highly homogenous. Besides, the women included in the test
groups have lived in the area comprised by the study, practi-
cally from birth.
Gene mutation may result in altered activation of other
genes and/or their products having a major role in the same
metabolic pathways. Such a nature of effect has been shown in
studies where participation of allele B of the VDR gene was
associated with the increased risk of osteoporosis. Other stud-
ies revealed low BMD scores upon subordination to allele B
of theVDR gene [31, 32]. Future studies are needed to confirm
the validity of these observations.
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